Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer immunotherapy cocktail shows promise but trial halted early

NCT ID NCT04832854

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested two immunotherapy drugs (tiragolumab and atezolizumab) with or without chemotherapy in 50 people with early-stage non-small cell lung cancer that could be surgically removed. The goal was to see if the treatment shrank tumors before surgery and prevented return after. The study was terminated early, so results are limited, but researchers looked at surgical safety and tumor response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tiragolumab and atezolizumab (immunotherapy drugs) with or without platinum-based chemotherapy
What this could lead to
If successful, this combination could improve tumor shrinkage before surgery and reduce recurrence after surgery for lung cancer patients.
What could go wrong
The trial was terminated early, so data is limited. Immunotherapy can cause immune-related side effects, and adding chemo increases toxicity. Results may not apply to all lung cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Apr 2021

Finished

Mar 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key inclusion criteria: * Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology * Eligible for R0 resection with curative intent at the time of screening * Adequate pulmonary function to be eligible for surgical resection with curative intent * Eligible to receive a platinum-based chemotherapy regimen * Measurable disease, as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Availability of a representative tumor specimen that is suitable for determination of PD-L1 status * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Normal life expectancy, excluding lung cancer mortality risk * Adequate hematologic and end-organ function * Negative human immunodeficiency virus (HIV) test at screening * Negative serology for active hepatitis B virus (HBV) and active hepatitis C virus (HCV) at screening Key Exclusion Criteria: * NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified * Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC * Any prior therapy for lung cancer * Active or history of autoimmune disease or immune deficiency * History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan * Active tuberculosis * Significant cardiovascular disease * NSCLC with an activating EGFR mutation or ALK fusion oncogene * Known c-ros oncogene 1 (ROS1) rearrangement * History of malignancy other than NSCLC within 5 years prior to screening, with the exception of malignancies with negligible risk of metastasis or death * Severe infection within 4 weeks prior to initiation of study treatment or any active infection that, in the opinion of the investigator, could impact patient safety * Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies * Treatment with systemic immunostimulatory agents * Treatment with systemic immunosuppressive medication * Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer (NSCLC)

Contacts and locations

Locations

  • City of Hope Cancer Center

    Duarte, California, 91010, United States

  • Columbia University

    New York, New York, 10032-3725, United States

  • Complejo Hospitalario Universitario A Coruña (CHUAC)

    A Coruña, 15006, Spain

  • Corporacio Sanitaria Parc Tauli

    Sabadell, Barcelona, 08208, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Puerta de Hierro

    Majadahonda, Madrid, 28222, Spain

  • ICO L'Hospitalet

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Kantonsspital Baden

    Baden, 5404, Switzerland

  • Kantonsspital Graubünden Medizin Onkologie

    Chur, 7000, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, 9007, Switzerland

  • Kantonsspital Winterthur

    Winterthur, 8401, Switzerland

  • NYU Cancer Center

    New York, New York, 10016, United States

  • Peter Maccallum Cancer Institute

    Melbourne, Victoria, 3000, Australia

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • St. Vincent's Hospital

    Gyeonggi-do, 16247, South Korea

  • Sunshine Coast University Hospital

    Birtinya, Queensland, 4575, Australia

  • University of Southern California

    Los Angeles, California, 90033, United States

  • UniversitätsSpital Zürich

    Zurich, 8091, Switzerland

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, 08035, Spain

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Winthrop Univ Hospital

    Mineola, New York, 11501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.